Kardiket

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kardiket

Quick Facts

Property Description
Active Ingredient Isosorbide Dinitrate
Form Tablet (Oral and Sublingual)
Pharmacological Class Nitrate Vasodilator
Common Use Reducing strain on the heart muscle
Origin Synthetic Small Molecule

What Type of Drug is Kardiket?

Kardiket is a medicine containing the active ingredient isosorbide dinitrate, and it belongs to the high-level drug class of nitrate vasodilators. This class is a type of cardiovascular medicine primarily used to affect the body's blood vessels. Isosorbide dinitrate is officially designated as a coronary vasodilator, a classification clinically recognized for its direct action on vascular smooth muscle. It is classified as a synthetic small molecule, meaning it is a chemically manufactured compound, rather than being derived from a natural source.

How is Kardiket Supplied?

Kardiket is typically supplied as a tablet, often available in both standard oral and fast-acting sublingual forms. It is a single-entity medicine, relying solely on the effect of isosorbide dinitrate. The different delivery types—swallowing for standard absorption (oral route) or placing it under the tongue for rapid effect (sublingual route)—offer flexibility to the patient. The sublingual forms are specifically designed for prompt dissolution and absorption when rapid onset is beneficial.

What is the General Goal of This Medicine?

The primary purpose of Kardiket is to widen blood vessels, which serves to reduce the workload placed on the heart. The medicine works by being converted into a substance called nitric oxide, which is a natural signal in the body that causes the smooth muscle in vessel walls to relax and widen. This widening effect, or vasodilation, is beneficial because it allows blood to flow more easily through the circulatory system, easing the overall strain on the heart muscle and improving circulation in the heart itself.

Regulatory References

  1. Isosorbide: MedlinePlus Drug Information

What side effects are possible with Kardiket?

Official Adverse Reactions and Safety Profile

Isosorbide dinitrate, the active ingredient in Kardiket, has an official safety profile primarily characterized by effects related to its potent vasodilation. Regulatory agencies categorize adverse reactions by frequency and affected system-organ class.

Frequency Common Adverse Reactions
Very Common Headache, cited as the most frequent side effect, often subsides within the initial days of therapy.
Common Hypotension (decreased blood pressure), Orthostatic Hypotension (dizziness upon standing), and Reflex Tachycardia (rapid heart rate).
Uncommon Nausea, Vomiting, Allergic skin reactions, and paradoxical Aggravation of Symptomatic Angina Pectoris due to severe hypotension.

Serious adverse reactions are explicitly documented in regulatory labeling. These include severe Hypotension which may lead to collapse or syncope, and the risk of Methemoglobinemia (a potentially serious condition affecting blood oxygen capacity). Very rare reactions include severe dermatological events like Exfoliative Dermatitis.

Safety Considerations

The official labeling outlines specific safety constraints. Use is formally contraindicated in conditions such as severe hypotension, severe anemia, shock, and when used concurrently with certain medications (e.g., PDE-5 inhibitors) due to the risk of life-threatening hypotension.

Time-related safety patterns indicate that risks of headache and hypotension are higher during the initiation of therapy and with dose increases. Tolerance to the therapeutic effect may develop with long-term, uninterrupted exposure. Safety information for the pediatric population is not established, and caution is advised for older adults due to increased risks of orthostatic hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official regulatory profile for an overdose of Kardiket (Isosorbide Dinitrate) is defined primarily by its severe effects on the cardiovascular and nervous systems.

Property Documented Regulatory Description
Documented Overdose Presentations Severe Hypotension (prompt fall in blood pressure); persistent and throbbing headache; vertigo; confusion; palpitations; vomiting; and potential bloody diarrhea. The skin may be flushed and perspiring, later becoming cold and cyanotic.
Physiological Systems Affected Cardiovascular, Central Nervous System, and Hematologic (risk of Methemoglobinemia).
Population-Specific Notes Patients who are volume depleted or already hypotensive may exhibit marked sensitivity, potentially leading to a severe hypotensive response with even small doses.
Emergency-Response Statements Seek immediate medical attention for any suspected overdose. Contact emergency services or a Poison Control center immediately.

Official Overdose Statements:

  • Severe outcomes can include syncope, convulsions (seizures), and circulatory collapse.
  • No specific antagonist to the primary vasodilator effects is known according to regulatory prescribing information.
  • Management involves supportive care, including passive elevation of the patient's extremities and intravenous fluid administration to address volume depletion.
  • Careful clinical or hemodynamic monitoring is required in the overdose setting.
  • The specific, life-threatening complication of Methemoglobinemia (which causes cyanosis) is treated with Methylene Blue.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by its core risk of severe hemodynamic instability, characterized by marked hypotension and secondary neurological complications. This profile necessitates immediately seeking medical attention for any suspected ingestion, with mandatory supportive procedures focusing on restoring central fluid volume and continuous hemodynamic observation.

Therapeutic Uses of Kardiket

What Kardiket Treats: Main Uses and Benefits

This medication may be part of symptomatic management for cardiovascular conditions, primarily addressing symptoms related to physical discomfort. It is commonly used to prevent and manage stable angina pectoris and is considered relevant as an adjunctive treatment in the management of congestive heart failure (CHF).

In clinical settings, Kardiket is applied across two main scenarios: maintenance therapy for recurrent anginal episodes, and short-term symptomatic assistance for acute episodes of chest pain or for preemptive use when symptoms may be provoked by activity. Regular use helps address symptom clusters that may become intense or disruptive, such as recurrent chest pain, and supports general well-being during symptomatic phases.

“This approach is relevant when supportive symptom management is appropriate, may assist with maintaining functional stability.”

For those with chronic symptoms, the main therapeutic benefit is prophylaxis, which plays a role in managing the frequency and intensity of painful episodes. For patients with CHF, it helps address symptoms related to systemic imbalance, such as shortness of breath or congestion, and contributes to easing the overall symptom load.


Quick Fact: Relief for Angina Pectoris Kardiket is commonly used to help manage the overall symptom burden associated with chest pain, assists with maintaining functional stability and is relevant for easing recurrent episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Kardiket's use is officially defined by specific population eligibility and exclusion criteria established by regulatory authorities.

Absolute Contraindications (Cannot Use)

The medicine is strictly forbidden for individuals with known hypersensitivity to any organic nitrate or those concurrently taking Phosphodiesterase Type 5 (PDE-5) inhibitors (such as sildenafil or tadalafil) or the soluble guanylate cyclase stimulator riociguat. Use is also prohibited in patients with marked anaemia, circulatory collapse, hypertrophic obstructive cardiomyopathy (HOCM), or conditions associated with increased intracranial pressure, including cerebral hemorrhage.

Age and Conditional Eligibility

Use is established for the adult and older adult populations, though caution is necessary for older adults due to higher susceptibility to hypotension. The safety and effectiveness of Kardiket in the pediatric population have not been established, and its use is generally not recommended in children and adolescents.

Conditional use requires caution in patients with severe hepatic (liver) or renal (kidney) disease, or in those who are severely hypotensive or volume depleted. For pregnant women, the medicine is classified as Pregnancy Category C and should be used only if the potential benefit justifies the potential risk. Caution is advised for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Kardiket (Isosorbide Dinitrate) around high-risk prohibitions and documented effects on blood pressure and drug exposure.


Formal Contraindicated Combinations

The most significant interaction involves medicines that are contraindicated for co-administration due to the official risk of severe hypotension, syncope, or myocardial ischemia.

Classification Interacting Substances (Examples)
PDE5 Inhibitors Sildenafil, Tadalafil, Vardenafil
sGC Stimulators Riociguat

Pharmacodynamic and Exposure-Altering Interactions

Interactions involving an additive vasodilating effect are documented with other blood pressure-lowering agents, including other vasodilators and antihypertensives. This additive effect may lead to excessive lowering of systemic blood pressure, as stated in regulatory sources. Co-ingestion of alcohol is also documented to exhibit additive vasodilating effects, which may increase the risk of associated adverse effects like dizziness.

The regulatory label also documents pharmacokinetic interactions mediated by the CYP3A4 enzyme. Co-administration with known CYP3A4 Inducers may officially decrease the level or effect of isosorbide dinitrate, while CYP3A4 Inhibitors may officially increase the level or effect of the medicine.

Mechanism of Action

Molecular Bioactivation and NO Release

The drug acts as a prodrug that undergoes enzymatic conversion by specific cellular enzymes to release its active signaling molecule, Nitric Oxide ( NO). This NO immediately targets and activates the enzyme Soluble Guanylyl Cyclase ( sGC) inside the vascular smooth muscle cells, triggering the fundamental NO-sGC-cGMP cascade.


Modulation of Vascular Smooth Muscle Tone

The activated sGC dramatically increases the production of the intracellular messenger cGMP (Cyclic Guanosine Monophosphate). High cGMP levels initiate a sequence that ultimately causes the dephosphorylation of proteins controlling the muscle's contractile state, leading to generalized relaxation and widening of the blood vessels (vasodilation).


️ Hemodynamic Effect: Reduction of Cardiac Work

The vasodilation predominantly affects large veins, causing venous pooling which decreases the volume of blood returning to the heart ( Preload). By also reducing the resistance in the arterial system ( Afterload), this mechanism limits the mechanical force and tension required for the heart to pump, thereby reducing the required cardiac work.

Dosage and Administration Information

How to Use Kardiket

The usage of this medication is structured around its distinct routes and specific administration patterns. It is available as an oral tablet for scheduled systemic absorption and as a fast-acting sublingual tablet for immediate relief, enabling use for both chronic management and acute scenarios.

Official Administration and Dosing Principles

Use Pattern Description
Route of Administration Approved for both Oral and Sublingual administration, with specific forms tied to each route.
Dosing for Prophylaxis Long-term schedules typically start at 5 mg to 20 mg, taken two or three times daily, with maintenance doses reaching up to 40 mg.
Acute Relief Pattern Sublingual doses are administered at 2.5 mg to 5 mg, with a procedural restriction not to exceed three doses within 15 to 30 minutes.
Handling Constraints Extended-release forms must be swallowed whole and not crushed or chewed; sublingual forms must dissolve completely under the tongue.

The Mandatory Nitrate-Free Interval

A central usage principle for chronic therapy is the inclusion of a daily dose-free interval of at least 14 hours. This scheduled period of non-use is utilized to prevent the development of pharmacological tolerance, thereby sustaining the medicine's effectiveness over time.

Population-Specific Use

Dosing for older adults should be initiated with caution, generally starting at the lower end of the recommended range. Furthermore, the safety and efficacy of the medication have not been established in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Agent's Activity

Research has explored the preliminary understanding of how the agent acts on the body. This includes studies focusing on the peripheral nervous system and inflammatory markers. Researchers note that this early work has primarily been characterized in in vitro models and preliminary animal studies.


Efficacy and Safety Profile

Initial Phase I and II Trials

Early studies have investigated whether the agent affects the quality of life among subjects with chronic indications. Long-term safety data in populations over 65 have been examined in studies. Research also evaluated whether the agent affects the participant's self-reported pain scores. Adverse events were monitored, and safety data were compiled for the participants in these initial studies.

Core Phase III Research

Clinical trials collected safety data, including tracking the incidence of adverse events and serious adverse events. The primary outcome measure in the largest trial was a change in the overall disease activity score over 12 weeks. Secondary outcomes explored participant-reported symptom changes.

Studies evaluated the combination of X and Y and investigated whether it correlated with symptom changes over time. Research protocols investigated different dosing regimens and evaluated various outcome measures. Further investigation is ongoing to clarify the nature of any observed correlations.

Key Studies & References

  1. Isosorbide - StatPearls - NCBI Bookshelf (Review of Mechanism of Action and Adverse Effects)
  2. Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus (General review on safety in age 65+ populations)

Frequently Asked Questions (FAQ)

Common questions about Kardiket (FAQ)

Q: Can Kardiket be taken long-term?

Official prescribing documents outline long-term use for this medication. When taken chronically, the required usage includes a daily period without the medicine, known as a dose-free interval. This scheduled period is intended to help prevent the development of pharmacological tolerance and maintain the medicine’s effectiveness over time.

Q: How quickly does Kardiket start working after I take it?

According to official product information, the sublingual (under the tongue) form is described as being available for use in acute scenarios due to its more rapid absorption. Official information notes that the sublingual form has an onset of action cited to occur around 15 minutes after administration.

Q: Is Kardiket a blood pressure medicine?

Kardiket is officially classified as a nitrate vasodilator, primarily intended to prevent chest pain and reduce the strain on the heart muscle. Its mechanism involves widening blood vessels, which does result in lowered blood pressure. However, it is generally not approved or consistently classified as a primary, first-line treatment for uncomplicated high blood pressure (hypertension).

Q: How long does the effect of Kardiket usually last?

Official product information indicates that the duration of effect varies by the form used. The standard oral tablet's effects typically last for several hours. If an extended-release form is used, the effect is often cited as providing a therapeutic effect for 8 to 10 hours.

Q: Are there any food restrictions when using Kardiket?

According to regulatory labeling, specific interactions between this medicine and food have not been established. The official documentation indicates that the tablets may generally be taken with or without food.

Q: What if I accidentally miss a dose of Kardiket?

Official patient guidance for scheduled use describes procedures for handling missed doses. It typically advises that if the time for the next scheduled dose is very near (often defined based on the medicine's form), the missed dose is skipped entirely. Regulatory instructions caution against taking extra medicine or a double dose to make up for a missed one.

Q: Does Kardiket interact with supplements like magnesium or vitamin D?

Regulatory documentation generally indicates that specific interactions with many common herbal products or dietary supplements have not been established. Official guidance emphasizes the importance of providing the healthcare team with a full list of all products, including supplements.

Q: How is Kardiket different from regular nitroglycerin?

Both are classified as nitrate medicines, but they have different clinical descriptions regarding their onset of action. Official prescribing information states that Kardiket is not the preferred choice for aborting an acute symptom episode because its onset is not as rapid as sublingual nitroglycerin, indicating its use is for scheduled management.

Q: Can I take Kardiket if I'm taking a blood thinner?

Official drug interaction documents caution that this medicine may interact with a wide range of other substances, including certain cardiovascular medications. Regulatory labeling emphasizes that a patient's full medication list, including any blood thinners or anti-platelet agents, should be reviewed by a healthcare professional. This is consistent with the need to manage potential cardiovascular drug interactions.

Q: Is there a generic version of Kardiket available?

Yes, the active ingredient contained in Kardiket, which is isosorbide dinitrate, is widely available in generic form. Generic versions are supplied in various preparations and meet the same regulatory standards as the brand-name product.

Q: What happens if I stop taking Kardiket suddenly?

Regulatory patient information contains warnings about the risks associated with suddenly discontinuing the medicine. Stopping the regular, chronic use of this medication without appropriate medical guidance may potentially lead to a worsening of the underlying symptoms.

Q: Why do some people take Kardiket for reasons other than chest pain?

While the primary approved indication is to prevent chest pain, official prescribing information notes that the medicine is sometimes used for an additional purpose. This can include using it alongside other specific medications as part of a treatment regimen for heart failure.

Q: Can I drive or operate machinery while taking Kardiket?

Official regulatory patient warnings describe the risk of engaging in activities that require mental alertness, such as driving or operating heavy machinery. This caution is due to the possibility of experiencing common side effects like dizziness or lightheadedness, particularly when first starting the therapy.

Q: Is it normal to feel tired after taking Kardiket?

Fatigue or unusual weakness is generally not listed as a common, standalone side effect in official regulatory documents. However, official warnings do note that unusual weakness is sometimes cited as a potential symptom of certain rare but serious adverse reactions, such as methemoglobinemia.

Q: Are there different brand names for the same active ingredient as Kardiket?

Yes, the active pharmaceutical ingredient found in Kardiket (isosorbide dinitrate) is marketed globally under several different brand names. Examples include Isordil and Dilatrate-SR, among others.

Q: What ingredients are used as inactive fillers in Kardiket tablets?

Official regulatory labeling provides a complete list of inactive ingredients, which are the components used to formulate the physical tablet. These can include excipients such as lactose anhydrous, magnesium stearate, and microcrystalline cellulose.

Q: Is Kardiket considered a Schedule drug or a controlled substance?

The active ingredient in this medicine, isosorbide dinitrate, is not classified as a controlled substance. This classification means it is not listed on the schedules maintained by the U.S. Drug Enforcement Administration (DEA).

Q: What information is published by the FDA about Kardiket?

The U.S. Food and Drug Administration (FDA) provides comprehensive regulatory documentation regarding this medication. This information covers major areas such as the drug's officially approved uses (indications), detailed dosing and administration guidelines, a full list of warnings and precautions, and a summary of known side effects and drug interactions.

Q: Can taking Kardiket affect the results of other medical tests?

Yes, regulatory information notes that nitrates, the class of drug Kardiket belongs to, may interfere with certain laboratory tests. Specifically, they can potentially interact with the Zlatkis-Zak color reaction used to measure serum cholesterol, which could lead to falsely low readings.

Q: Is Kardiket used to treat high blood pressure (hypertension)?

While this medicine has the effect of relaxing blood vessels and can lower blood pressure, its official and primary use is for preventing chest pain and reducing the workload on the heart. It is not generally approved as a first-line treatment for uncomplicated, chronic high blood pressure (hypertension).

Q: Can I take ibuprofen or aspirin while using Kardiket?

Official patient guidance from regulatory bodies suggests caution regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs), which include common painkillers like ibuprofen or aspirin. Regular use of these pain relievers may potentially worsen the underlying condition the medicine is being taken for.

How should Kardiket be stored and disposed of?

Storage Conditions

Kardiket must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be kept from freezing and stored away from excess heat.

Regulatory labeling requires the medication to be protected from both light and moisture. It must be kept in the container it came in and maintained tightly closed to preserve its stability.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children. Do not keep or use the product past its expiration date.

Disposal of any unused or expired Kardiket should be managed by consulting a healthcare professional or pharmacist on the appropriate method, ensuring compliance with local requirements for discarding medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kardiket found in:

A-Z Index: